We are aware of an issue causing the title of some ARTG entries to disappear. We are investigating as a priority and hope to have this resolved as soon as possible.
About this guideline
Overseas effective date: 1 December 2013
Replaces: 3AB7a Use of transgenic animals in the manufacture of biological medicinal products for human use (adopted by TGA 12 February 2002) and concept paper EMEA/CHMP/BWP/134153/2009 on this topic (provided for information 26 March 2010)
Categories: Biologicals | active substance | Manufacture, characterisation and control of the active substance
TGA annotations: Nil
- Where EU guidelines adopted in Australia include references to EU legislation (including EC Directives and Regulations), the requirements contained in the referenced EU legislation are not applicable to the evaluation of medicines by the TGA.
- All documents and other content published by the European Medicines Agency (EMA) on this website are under the copyright and other intellectual property rights ownership of the EMA. Please refer to Legal notice | European Medicines Agency for further information.
For more information see International scientific guidelines adopted in Australia.